MedPath

Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma

Phase 4
Completed
Conditions
Allergic Asthma
Registration Number
NCT00492076
Lead Sponsor
ALK-Abelló A/S
Brief Summary

The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.

Detailed Description

The control of mild-moderate persistent asthma include the need of concomitant medication, as inhaled corticosteroids. However, compliance in perennial asthma is low. The aim of this study is to assess the possibility to reduce the need of concomitant medication through a short-course of subcutaneous immunotherapy.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Mild/moderate persistent asthma
  • Positive skin prick test or specific IgE to mites
  • Age: 14-55 years old
Exclusion Criteria
  • Immunotherapy contraindications
  • Allergy to other inhalant allergens
  • Previous immunotherapy (5 years)with mites

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Reduction in inhaled corticosteroids4 months
Secondary Outcome Measures
NameTimeMethod
Reduction in symptoms and rescue medication Tolerability4 months

Trial Locations

Locations (1)

Hospital Virgen del Camino, Allergology Service

🇪🇸

Pamplona, Navarra, Spain

Hospital Virgen del Camino, Allergology Service
🇪🇸Pamplona, Navarra, Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.